Cancer clinical trials in Liestal
11 open trials with at least one site in Liestal, according to ClinicalTrials.gov, updated on October 28, 2026.
These results are indicative and do not replace medical advice — discuss them with your doctor.
Open trials
- Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%
NCT07020065RecruitingPhase 2
- Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK
NCT06358573RecruitingPhase 2
- A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
NCT07647328RecruitingPhase 3
- DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
NCT06989112RecruitingPhase 3
- A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
NCT06492616RecruitingPhase 3
- DESTINY Breast Respond HER2-(Ultra)Low Europe
NCT05945732Recruiting
- MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)
NCT04111978RecruitingPhase 3
- Extended vs. No Pelvic Lymph Node Dissection During Radical Prostatectomy. DISSECTION 2.0.
NCT06776172Recruiting
- Swiss Severe Asthma Register
NCT03984253Recruiting
- Circulating Tumor Cells (CTC) in Cancer
NCT04520672Recruiting
- Safety and Modulation of Adaptive Immunity by Iscador® Qu Viscum Album Extract in Patients With Advanced, Recurrent or Metastatic Cancers Treated With Immune Checkpoint Inhibitors
NCT06408688RecruitingPhase 4